Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells

Journal of Leukocyte Biology

Volumn 76, Issue 2, 2004, Pages 338-351

  Spaner, David E ^a,b,c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cytokines; Human; Signal transduction; Tumor immunity

Indexed keywords

ALPHA2B INTERFERON; CANCER VACCINE; CYTOKINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 6; MELANOMA VACCINE; PHOSPHOTRANSFERASE INHIBITOR; PROSTAGLANDIN E2; PROTEIN KINASE B; RAS PROTEIN; STAT3 PROTEIN; VASCULOTROPIN;

CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; CONFERENCE PAPER; DRUG EFFICACY; DRUG MEGADOSE; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; T LYMPHOCYTE; TUMOR CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 3442881583     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0104016     Document Type: Conference Paper

References (189)

1. Pardoll, D. M. (1998) Cancer vaccines. Nat. Med. 4, 525-531.
2. Rosenberg, S. A. (2001) Progress in human tumour immunology and immunotherapy. Nature 411, 380-384.
3. Wallack, M. K., Sivanandham, M., Balch, C. M., Urist, M. M., Bland, K. I., Murray, D., Robinson, W. A., Flaherty, L. E., Richards, J. M., Bartolucci, A. A. (1995) A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 75, 34-42.
4. Gitelson, E., Hammond, C., Mena, J., Lorenzo, M., Buckstein, R., Berinstein, N., Imrie, K. E., Spaner, D. E. (2003) Chronic lymphocytic leukemia-reactive T cells during tumor progression and after oxidized autologous tumor cell vaccines. Clin. Cancer Res. 9, 1656-1665.
5. Astsaturov, I., Petrella, T., Bagriacik, E. U., de Benedette, M., Uger, R., Lumber, G., Berinstein, N., Elias, I., Iscoe, N., Hammond, C., Hamilton, P., Spaner, D. E. (2003) Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-α2b: implications for cancer vaccines. Clin. Cancer Res. 9, 4347-4355.
6. Germain, R. N., Margulies, D. H. (1993) The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol. 11, 403-450.
7. Sharpe, A. H., Freeman, G. J. (2002) The B7-CD28 superfamily. Nat. Rev. Immunol. 2, 116-126.
8. Baurain, J. F., Colau, D., van Baren, N., Landry, C., Martelange, V., Vikkula, M., Boon, T., Coulie, P. G. (2000) High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene. J. Immunol. 164, 6057-6066.
9. Kolb, H. J., Holler, E. (1997) Adoptive immunotherapy with donor lymphocyte transfusions. Curr. Opin. Oncol. 9, 139-145.
10. Boon, T., Coulie, P. G., Van den Eynde, B. (1997) Tumor antigens recognized by T cells. Immunol. Today 18, 267-268.
11. Van den Eynde, B. J., van der Bruggen, P. (1997) T cell defined tumor antigens. Curr. Opin. Immunol. 9, 684-693.
12. van der Bruggen, P., Bastin, J., Gajewski, T., Coulie, P. G., Boel, P., De Smet, C., Traversari, C., Townsend, A., Boon, T. (1994) A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol. 24, 3038-3043.
13. Mandelcom-Monson, R. L., Shear, N. H., Yau, E., Sambhara, S., Barber, B. H., Spaner, D., DeBenedette, M. A. (2003) Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. J. Invest. Dermatol. 121, 550-556.
14. Berd, D., Maguire Jr., H. C., Schuchter, L. M., Hamilton, R., Hauck, W. W., Sato, T., Mastrangelo, M. J. (1997) Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J. Clin. Oncol. 15, 2359-2370.
15. Pardoll, D. M. (1999) Inducing autoimmune disease to treat cancer. Proc. Natl. Acad. Sci. USA 96, 5340-5342.
16. McMichael, A. J., O'Callaghan, C. A. (1998) A new look at T cells. J. Exp. Med. 187, 1367-1371.
17. Decker, T., Schneller, F., Kronschnabl, M., Dechow, T., Lipford, G. B., Wagner, H., Peschel, C. (2000) Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype. Exp. Hematol. 28, 558-568.
18. Dudley, M. E., Rosenberg, S. A. (2003) Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer 3, 666-675.
19. Ochsenbein, A. F., Sierro, S., Odermatt, B., Pericin, M., Karrer, U., Hermans, J., Hemmi, S., Hengartner, H., Zinkemagel, R. M. (2001) Roles of tumour localization, second signals, and cross priming in cytotoxic T-cell induction. Nature 411, 1058-1064.
20. Dummer, R., Yue, F. Y., Pavlovic, J., Geertsen, R., Dohring, C., Moelling, K., Burg, G. (1998) Immune stimulatory potential of B7.1 and B7.2 retrovirally transduced melanoma cells: suppression by interleukin 10. Br. J. Cancer 77, 1413-1419.
21. Takeuchi, H., Maehara, Y., Tokunaga, E., Koga, T., Kakeji, Y., Sugimachi, K. (2003) Prognostic value of preoperative immunosuppressive acidic protein levels in patients with gastric carcinoma. Hepatogastroenterology 50, 289-292.
22. Agrawal, B., Krantz, M. J., Reddish, M. A., Longenecker, B. M. (1998) Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat. Med. 4, 43-49.
23. Tas, M. P., Simons, P. J., Balm, F. J., Drexhage, H. A. (1993) Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer: in vitro restoration of this immunosuppression by thymic hormones. Cancer Immunol. Immunother. 36, 108-114.
24. Xie, J., Wang, Y., Freeman III, M. E., Barlogie, B., Yi, Q. (2003) β2-Microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood 101, 4005-4012.
25. Derynck, R., Akhurst, R. J., Balmain, A. (2001) TGF-β signaling in tumor suppression and cancer progression. Nat. Genet. 29, 117-129.
26. Blobe, G. C., Schiemann, W. P., Lodish, H. F. (2000) Role of transforming growth factor β in human disease. N. Engl. J. Med. 342, 1350-1358.
27. DeCoteau, J. F., Knaus, P. I., Yankelev, H., Reis, M. D., Lowsky, R., Lodish, H. F., Kadin, M. E. (1997) Loss of functional cell surface transforming growth factor β (TGF-β) type 1 receptor correlates with insensitivity to TGF-β in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 94, 5877-5881.
28. Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W., Vogelstein, B., (1995) Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 268, 1336-1338.
29. Hahn, S. A., Schutte, M., Hoque, A. T., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., Kern, S. E. (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271, 350-353.
30. Friedenberg, W. R., Salzman, S. A., Phan, S. M., Burmester, J. K. (1999) Transforming growth factor-β and multidrug resistance in chronic lymphocytic leukemia. Med. Oncol. 16, 110-118.
31. Reed, J. A., McNutt, N. S., Prieto, V. G., Albino, A. P. (1994) Expression of transforming growth factor-β 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression. Am. J. Pathol. 145, 97-104.
32. Tsushima, H., Ito, N., Tamura, S., Matsuda, Y., Inada, M., Yalmuchi, I., Imai, Y., Nagashima, B., Misawa, H., Takeda, H., Matsuzawa, Y., Kawata, S. (2001) Circulating transforming growth factor β1 as a predictor of liver metastasis after resection in colorectal cancer. Clin. Cancer Res. 7, 1258-1262.
33. Hasegawa, Y., Takanashi, S., Kanehira, Y., Tsushima, T., Imai, T., Okumura, K. (2001) Transforming growth factor-β1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 91, 964-971.
34. Ivanovic, V., Melman, A., Davis-Joseph, B., Valcic, M., Geliebter, J. (1995) Elevated plasma levels of TGF-β 1 in patients with invasive prostate cancer. Nat. Med. 1, 282-284.
35. Nakamura, M., Katano, M., Kuwahara, A., Fujimoto, K., Miyazaki, K., Morisaki, T., Mori, M. (1998) Transforming growth factor β1 (TGF-β1) is a preoperative prognostic indicator in advanced gastric carcinoma. Br. J. Cancer 78, 1373-1378,
36. Li, C., Wang, J., Wilson, P. B., Kumar, P., Levine, E., Hunter, B. D., Kumar, S. (1998) Role of transforming growth factor β3 in lymphatic metastasis in breast cancer. Int. J. Cancer 79, 455-459.
37. Cook, G., Campbell, J. D., Carr, C. E., Boyd, K. S., Franklin, I. M. (1999) Transforming growth factor β from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes. J. Leukoc. Biol. 66, 981-988.
38. Smyth, M. J., Strobl, S. L., Young, H. A., Ortaldo, J. R., Ochoa, A. C. (1991) Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-β. J. Immunol. 146, 3289-3297.
39. Boutard, V., Havouis, R., Fouqueray, B., Philippe, C., Moulinoux, J. P., Baud, L. (1995) Transforming growth factor-β stimulates arginase activity in macrophages. Implications for the regulation of macrophage cytotoxicity. J. Immunol. 155, 2077-2084.
40. Rodriguez, P. C., Zea, A. H., DeSalvo, J., Culotta, K. S., Zabaleta, J., Quiceno, D. G., Ochoa, J. B., Ochoa, A. C. (2003) L-arginine consumption by macrophages modulates the expression of CD3 ζ chain in T lymphocytes. J. Immunol. 171, 1232-1239.
41. Favoni, R. E., de Cupis, A. (2000) The role of polypeptide growth factors in human carcinomas: new targets for a novel pharmacological approach. Pharmacol. Rev. 52, 179-206.
42. Bellamy, W. T. (2001) Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin. Oncol. 28, 551-559.
43. Ohm, J. E., Gabrilovich, D. I., Sempowski, G. D., Kisseleva, E., Parman, K. S., Nadaf, S., Carbone, D. P. (2003) VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101, 4878-4886.
44. Kusmartsev, S., Cheng, F., Yu, B., Nefedova, Y., Sotomayor, E., Lush, R., Gabrilovich, D. (2003) All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 63, 4441-4449.
45. Mahnke, K., Schmitt, E., Bonifaz, L., Enk, A. H., Jonuleit, H. (2002) Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunol. Cell Biol. 80, 477-483.
46. Kleindienst, P., Brocker, T. (2003) Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo. J. Immunol. 170, 2817-2823.
47. Trikha, M., Corringham, R., Klein, B., Rossi, J. F. (2003) Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin. Cancer Res. 9, 4653-4665.
48. Conze, D., Weiss, L., Regen, P. S., Bhushan, A., Weaver, D., Johnson, P., Rincon, M. (2001) Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res. 61, 8851-8858.
49. Lai, R., O'Brien, S., Maushouri, T., Rogers, A., Kantarjian, H., Keating, M., Albitar, M. (2002) Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia. Cancer 95, 1071-1075.
50. Kurzrock, R. (1997) Cytokine deregulation in hematological malignancies: clinical and biological implications. Clin. Cancer Res. 3, 2581-2584.
51. Adler, H. L., McCurdy, M. A., Kattan, M. W., Timme, T. L., Scardino, P. T., Thompson, T. C. (1999) Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J. Urol. 161, 182-187.
52. Diehl, S., Rincon, M. (2002) The two faces of IL-6 on Th1/Th2 differentiation. Mol. Immunol. 39, 531-536.
53. Yasukawa, H., Sasaki, A., Yoshimura, A. (2000) Negative regulation of cytokine signaling pathways. Annu. Rev. Immunol. 18, 143-164.
54. Cheng, F., Wang, H. W., Cuenca, A., Huang, M., Ghansah, T., Brayer, J., Kerr, W. G., Takeda, K., Akira, S., Schoenberger, S. P., Yu, H., Jove, B., Sotomayor, E. M. (2003) A critical role for Stat3 signaling in immune tolerance. Immunity 19, 425-436.
55. Tilley, S. L., Coffman, T. M., Koller, B. H. (2001) Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J. Clin. Invest. 108, 15-23.
56. Ferrandina, G., Lauriola, L., Zannoni, G. F., Fagotti, A., Fanfani, F., Legge, F., Maggiano, N., Gessi, M., Mancuso, S., Ranelletti, F. O., Scambia, G. (2002) Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann. Oncol. 13, 1205-1211.
57. 2: a novel paradigm for the induction of T-cell anergy. Cell. Immunol. 180, 124-131.
58. Sharma, S., Stolina, M., Yang, S. C., Baratelli, F., Lin, J. F., Atianzar, K., Leo, J., Zhu, L., Lin, Y., Huang, M., Dohadwala, M., Batra, R. K., Dubinett, S. M. (2003) Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin. Cancer Res. 9, 961-968.
59. Huang, M., Wang, J., Lee, P., Sharma, S., Mao, J. T., Meissner, H., Uyemura, K., Modlin, R., Wollman, J., Dubinett, S. M. (1995) Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res. 55, 3847-3853.
60. Vassilakopoulos, T. P., Nadali, G., Angelopoulou, M. K., Siakantaris, M. P., Dimopoulou, M. N., Kontopidou, F. N., Rassidakis, G. Z., Doussis-Anagnostopoulou, I. A., Hatzioannou, M., Vaiopoulos, G., Kittas, C., Sarris, A. H., Pizzolo, G., Pangalis, G. A. (2001) Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma. Haematologica 86, 274-281.
61. Kotenko, S. V., Pestka, S. (2000) Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes. Oncogene 19, 2557-2565.
62. Sharma, S., Stolina, M., Lin, Y., Gardner, B., Miller, P. W., Kronenberg, M., Dubinett, S. M. (1999) T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J. Immunol. 163, 5020-5028.
63. Elgert, K. D., Alleva, D. G., Mullins, D. W. (1998) Tumor-induced immune dysfunction: the macrophage connection. J. Leukoc. Biol. 64, 275-290.
64. Trikha, M., Nakada, M. T. (2002) Platelets and cancer: implications for antiangiogenic therapy. Semin. Thromb. Hemost. 28, 39-44.
65. Wei, W. Z., Morris, G. P., Kong, Y. C. (2004) Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol. Immunother. 53, 73-78.
66. Chen, W., Wahl, S. M. (2003) TGF-β: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev. 14, 85-89.
67. Shevach, E. M. (2002) CD4+ CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2, 389-400.
68. Liyanage, U. K., Moore, T. T., Joo, H. G., Tanaka, Y., Herrmann, V., Doherty, G., Drebin, J. A., Strasberg, S. M., Eberlein, T. J., Goedegebuure, P. S., Linehan, D. C. (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169, 2756-2761.
69. Sasada, T, Kimura, M., Yoshida, Y., Kanai, M., Takabayashi, A. (2003) CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98, 1089-1099.
70. Somasundaram, R., Jacob, L., Swoboda, R., Caputo, L., Song, H., Basak, S., Monos, D., Peritt, D., Marincola, F., Cai, D., Birebent, B., Bloome, E., Kim, J., Berencsi, K., Mastrangelo, M., Herlyn, D. (2002) Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-β. Cancer Res. 62, 5267-5272.
71. Ichihara, F., Kono, K., Takahashi, A., Kawaida, H., Sugai, H., Fujii, H. (2003) Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin. Cancer Res. 9, 4404-4408.
72. Wolf, A. M., Wolf, D., Steurer, M., Gastl, G., Gunsilius, E., Grubeck-Loebenstein, B. (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9, 606-612.
73. Woo, E. Y., Chu, C. S., Goletz, T. J., Schlienger, K., Yeh, H., Coukos, G., Rubin, S. C., Kaiser, L. R., June, C. H. (2001) Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61, 4766-4772.
74. Wang, H. Y., Lee, D. A., Peng, G., Guo, Z., Li, Y., Kiniwa, Y., Shevach, E. M., Wang, R. F. (2004) Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 20, 107-118.
75. Boussiotis, V. A., Chen, Z. M., Zeller, J. C., Murphy, W. J., Berezovskaya, A., Narula, S., Roncarolo, M. G., Blazar, B. R. (2001) Altered T-cell receptor + CD28-mediated signaling and blocked cell cycle progression in interleukin 10 and transforming growth factor-β-treated alloreactive T cells that do not induce graft-versus-host disease. Blood 97, 565-571.
76. O'Byrne, K. J., Dalgleish, A. G., Browning, M. J., Steward, W. P., Harris, A. L. (2000) The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur. J. Cancer 36, 151-169.
77. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., Schreiber, R. D. (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991-998.
78. Prehn, R. T. (1977) Immunostimulation of the lymphodependent phase of neoplastic growth. J. Natl. Cancer Inst. 59, 1043-1049.
79. Rak, J., Yu, J. L., Kerbel, R. S., Coomber, B. L. (2002) What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res. 62, 1931-1934.
80. Green, D. R., Evan, G. I. (2002) A matter of life and death. Cancer Cell 1, 19-30.
81. Downward, J. (2003) Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3, 11-22.
82. Reuter, C. W., Morgan, M. A., Bergmann, L. (2000) Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 96, 1655-1669.
83. Ozanne, B. W., McGarry, L., Spence, H. J., Johnston, I., Winnie, J., Meagher, L., Stapleton, G. (2000) Transcriptional regulation of cell invasion: AP-1 regulation of a multigenic invasion programme. Eur. J. Cancer 36, 1640-1648.
84. Rak, J., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., Kerbel, B. S. (1995) Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 55, 4575-4580.
85. Geiser, A. G., Kim, S. J., Roberts, A. B., Sporn, M. B. (1991) Characterization of the mouse transforming growth factor-β 1 promoter and activation by the Ha-ras oncogene. Mol. Cell. Biol. 11, 84-92.
86. Yoshimatsu, K., Altorki, N. K., Golijanin, D., Zhang, F., Jakobsson, P. J., Dannenberg, A. J., Subbaramaiah, K. (2001) Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin. Cancer Res. 7, 2669-2674.
87. Kretzschmar, M., Doody, J., Timokhina, I., Massague, J. (1999) A mechanism of repression of TGFβ/ Smad signaling by oncogenic Ras. Genes Dev. 13, 804-816.
88. Vivanco, I., Sawyers, C. L. (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2, 489-501.
89. Vanhaesebroeck, B., Alessi, D. R. (2000) The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J. 346, 561-576.
90. Burgering, B. M., Medema, R. H. (2003) Decisions on life and death: FOXO forkhead transcription factors are in command when PKB/Akt is off duty. J. Leukoc. Biol. 73, 689-701.
91. Fingar, D. C., Salama, S., Tsou, C., Harlow, E., Blenis, J. (2002) Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 16, 1472-1487.
92. Ali, I. U., Schriml, L. M., Dean, M. (1999) Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J. Natl. Cancer Inst. 91, 1922-1932.
93. Philp, A. J., Campbell, I. G., Leet, C., Vincan, E., Rockman, S. P., Whitehead, R. H., Thomas, R. J., Phillips, W. A. (2001) The phosphatidylinositol 3′-kinase p85α gene is an oncogene in human ovarian and colon tumors. Cancer Res. 61, 7426-7429.
94. Shayesteh, L., Lu, Y., Kuo, W. L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B., Gray, J. W. (1999) PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 21, 99-102.
95. Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K., Testa, J. R. (1996) Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl. Acad. Sci. USA 93, 3636-3641.
96. Gomez-Manzano, C., Fueyo, J., Jiang, H., Glass, T. L., Lee, H. Y., Hu, M., Liu, J. L., Jasti, S. L., Liu, T. J., Conrad, C. A., Yung, W. K. (2003) Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis. Ann. Neurol. 53, 109-117.
97. Martin, M., Schifferle, R. E., Cuesta, N., Vogel, S. N., Katz, J., Michalek, S. M. (2003) Role of the phosphatidylinositol 3 kinase-Akt pathway in the regulation of IL-10 and IL-12 by Porphyromonas gingivalis lipopolysaccharide. J. Immunol. 171, 717-725.
98. Hu, L., Hofmann, J., Lu, Y., Mills, G. B., Jaffe, R. B. (2002) Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 62, 1087-1092.
99. Buettner, R., Mora, L. B., Jove, R. (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 8, 945-954.
100. Turkson, J., Jove, R. (2000) STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19, 6613-6626.
101. Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., Darnell Jr., J. E. (1999) Stat3 as an oncogene. Cell 98, 295-303.
102. Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., Heller, R., Ellis, L. M., Karras, J., Bromberg, J., Pardoll, D., Jove, R., Yu, H. (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21, 2000-2008.
103. Benkhart, E. M., Siedlar, M., Wedel, A., Werner, T., Ziegler-Heitbrock, H. W. (2000) Role of Stat3 in lipopolysaccharide-induced IL-10 gene expression. J. Immunol. 165, 1612-1617.
104. Nefedova, Y., Huang, M., Kusmartsev, S., Bhattacharya, P., Cheng, P., Salup, R., Jove, R., Gabrilovich, D. (2004) Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. 172, 464-474.
105. Berman, D. M., Karhadkar, S. S., Maitra, A., Montes, D. O., Gerstenblith, M. R., Briggs, K., Parker, A. R., Shimada, Y., Eshleman, J. R., Watkins, D. N., Beachy, P. A. (2003) Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425, 846-851.
106. Giles, R. H., van Es, J. H., Clevers, H. (2003) Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta 1653, 1-24.
107. Nickoloff, B. J., Osborne, B. A., Miele, L. (2003) Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 22, 6598-6608.
108. Mckenzie, G. J., Young, L. L., Briend, E., Lamb, J. R., Dallman, M. J., Champion, B. R. (2003) Notch signalling in the regulation of peripheral T-cell function. Semin. Cell Dev. Biol. 14, 127-134.
109. Sherr, C. J., McCormick, F. (2002) The RB and p53 pathways in cancer. Cancer Cell 2, 103-112.
110. Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., Taniguchi, T. (2003) Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence. Nature 424, 516-523.
111. Chodosh, L. A. (2002) The reciprocal dance between cancer and development. N. Engl. J. Med. 347, 134-136.
112. Raz, R., Lee, C. K., Cannizzaro, L. A., d'Eustachio, P., Levy, D. E. (1999) Essential role of STAT3 for embryonic stem cell pluripotency. Proc. Natl. Acad. Sci. USA 96, 2846-2851.
113. Mendelsohn, J., Baselga, J. (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19, 6550-6565.
114. Foy, T. M., Fanger, G. R., Hand, S., Gerard, C., Bruck, C., Cheever, M. A. (2002) Designing HER2 vaccines. Semin. Oncol. 29, 53-61.
115. Lobell, R. B., Omer, C. A., Abrams, M. T., Bhimnathwala, H. G., Brucker, M. J., Buser, C. A., Davide, J. P., deSolms, S. J., Dinsmore, C. J., Ellis-Hutchings, M. S., Kral, A. M., Liu, D., Lumma, W. C., Machotka, S. V., Rands, E., Williams, T. M., Graham, S. L., Harman, G. D., Oliff, A. I., Heimbrook D. C., Kohl, N. E. (2001) Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res. 61, 8758-8768.
116. Strumberg, D., Voliotis, D., Moeller, J. G., Hilger, R. A., Richly, H., Kredtke, S., Beling, C., Scheulen, M. E., Seeber, S. (2002) Results of phase 1 pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int. J. Clin. Pharmacol. Ther. 40, 580-581.
117. Allen, L. F., Sebolt-Leopold, J., Meyer, M. B. (2003) CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin. Oncol. 30, 105-116.
118. DeSilva, D. R., Jones, E. A., Favata, M. F., Jaffee, B. D., Magolda, R. L., Trzaskos, J. M., Scherle, P. A. (1998) Inhibition of mitogen-activated protein kinase kinase blocks T cell proliferation but does not induce or prevent anergy. J. Immunol. 160, 4175-4181.
119. Sausville, E. A., Arbuck, S. G., Messmann, R., Headlee, D., Bauer, K. S., Lush, R. M., Murgo, A., Figg, W. D., Lahusen, T., Jaken, S., Jing, X., Roberge, M., Fuse, E., Kuwabara, T., Senderowicz, A. M. (2001) Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J. Clin. Oncol. 19, 2319-2333.
120. Luo, J., Manning, B. D., Cantley, L. C. (2003) Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4, 257-262.
121. Nepomuceno, R. R., Balatoni, C. E., Natkunam, Y., Snow, A. L., Krams, S. M., Martinez, O. M. (2003) Rapamyein inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res. 63, 4472-4480.
122. Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., Jauch, K. W., Geissler, E. K. (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8, 128-135.
123. Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., Leeder, J. S., Freedman, M., Cohen, A., Gazit, A., Levitzki, A., Roifman, C. M. (1996) Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379, 645-648.
124. Burdelya, L., Catlett-Falcone, R., Levitzki, A., Cheng, F., Mora, L. B., Sotomayor, E., Coppola, D., Sun, J., Sebti, S., Dalton, W. S., Jove, R., Yu, H. (2002) Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. Mol. Cancer Ther. 1, 893-899.
125. Blaskovich, M. A., Sun, J., Cantor, A., Turkson, J., Jove, R., Sebti, S. M. (2003) Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/ signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 63, 1270-1279.
126. Hingorani, S. R., Tuveson, D. A. (2003) Targeting oncogene dependence and resistance. Cancer Cell 3, 414-417.
127. Sawyer, T. K. (2004) Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors. Expert Opin. Investig. Drugs 13, 1-19.
128. Aswald, J. M., Lipton, J. H., Aswald, S., Messner, H. A. (2002) Increased IFN-γ synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia. Cytokines Cell. Mol. Ther. 7, 143-149.
129. Turkson, J., Ryan, D., Kim, J. S., Zhang, Y., Chen, Z., Haura, E., Laudano, A., Sebti, S., Hamilton, A. D., Jove, R. (2001) Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem. 276, 45443-45455.
130. Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., et al. (1992) Targeted disruption of the mouse transforming growth factor-β 1 gene results in multifocal inflammatory disease. Nature 359, 693-699.
131. Wojtowicz-Praga, S. (2003) Reversal of tumor-induced immunosuppression by TGF-β inhibitors. Invest. New Drugs 21, 21-32.
132. Stander, M., Naumann, U., Dumitrescu, L., Heneka, M., Loschmann, P., Gulbins, E., Dichgans, J., Weller, M. (1998) Decorin gene transfer-mediated suppression of TGF-β synthesis abrogates experimental malignant glioma growth in vivo. Gene Ther. 5, 1187-1194.
133. Akhurst, R. J. (2002) TGF-β antagonists: why suppress a tumor suppressor? J. Clin. Invest. 109, 1533-1536.
134. Wojtowicz-Praga, S., Verma, U. N., Wakefield, L., Esteban, J. M., Hartmann, D., Mazumder, A., Verma, U. M. (1996) Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor β antibody and interleukin-2. J. Immunother. Emphasis Tumor Immunol. 19, 169-175.
135. Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., Rosenberg, S. A. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434.
136. Fiedler, W., Mesters, R., Tinnefeld, H., Loges, S., Staib, P., Duhrsen, U., Flasshove, M., Ottmann, O. G., Jung, W., Cavalli, F., Kuse, R., Thomalla, J., Serve, H., O'Farrell, A. M., Jacobs, M., Brega, N. M., Scigalla, P., Hossfeld, D. K., Berdel, W. E. (2003) A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 102, 2763-2767.
137. Gabrilovich, D. I., Ishida, T., Nadaf, S., Ohm, J. E., Carbone, D. P. (1999) Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 5, 2963-2970.
138. Almand, B., Resser, J. R., Lindman, B., Nadaf, S., Clark, J. I., Kwon, E. D., Carbone, D. P., Gabrilovich, D. I. (2000) Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 6, 1755-1766.
139. Yoshimatsu, K., Golijanin, D., Paty, P. B., Soslow, R. A., Jakobsson, P. J., DeLellis, R. A., Subbaramaiah, K., Dannenberg, A. J. (2001) Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin. Cancer Res. 7, 3971-3976.
140. Morecki, S., Yacovlev, E., Gelfand, Y., Trembovler, V., Shohami, E., Slavin, S. (2000) Induction of antitumor immunity by indomethacin. Cancer Immunol. Immunother. 48, 613-620.
141. Markewitz, A., Faist, E., Lang, S., Endres, S., Fuchs, D., Reichart, B. (1993) Successful restoration of cell-mediated immune response after cardiopulmonary bypass by immunomodulation. J. Thorac. Cardiovasc. Surg. 105, 15-24.
142. Loomis, W. H., Namiki, S., Hoyt, D. B., Junger, W. G. (2001) Hypertonicity rescues T cells from suppression by trauma-induced anti-inflammatory mediators. Am. J. Physiol. Cell Physiol. 281, C840-C848.
143. DeLong, P., Tanaka, T., Kruklitis, R., Henry, A. C., Kapoor, V., Kaiser, L. R., Sterman, D. H., Albelda, S. M. (2003) Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res. 63, 7845-7852.
144. Dong, C., Yang, D. D., Wysk, M., Whitmarsh, A. J., Davis, R. J., Flavell, R. A. (1998) Defective T cell differentiation in the absence of Jnk1. Science 282, 2092-2095.
145. Dong, C., Davis, R. J., Flavell, R. A. (2002) MAP kinases in the immune response. Annu. Rev. Immunol. 20, 55-72.
146. Beutler, B., Hoebe, K., Du, X., Ulevitch, R. J. (2003) How we detect microbes and respond to them: the Toll-like receptors and their transducers. J. Leukoc. Biol. 74, 479-485.
147. Hutter, D., Chen, P., Barnes, J., Liu, Y. (2000) Catalytic activation of mitogen-activated protein (MAP) kinase phosphatase-1 by binding to p38 MAP kinase: critical role of the p38 C-terminal domain in its negative regulation. Biochem. J. 352, 155-163.
148. Aguirre-Ghiso, J. A., Liu, D., Mignatti, A., Kovalski, K., Ossowski, L. (2001) Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol. Biol. Cell 12, 863-879.
149. Fan, M., Chambers, T. C. (2001) Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist. Updat. 4, 253-267.
150. Ehrke, M. J., Mihich, E., Berd, D., Mastrangelo, M. J. (1989) Effects of anticancer drugs on the immune system in humans. Semin. Oncol. 16, 230-253.
151. Spaner, D., Sheng-Tanner, X., Schuh, A. (2002) Aberrant regulation of superantigen responses during T cell reconstitution and GVHD in immunodeficient mice. Blood 100, 2216-2224.
152. Berd, D., Maguire Jr., H. C., Schuchter, L. M., Hamilton, R., Hauck, W. W., Sato, T., Mastrangelo, M. J. (1997) Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J. Clin. Oncol. 15, 2359-2370.
153. Mastrangelo, M. J., Berd, D., Maguire, H. J. (1986) The immuno-augmenting effects of cancer chemotherapeutic agents. Semin. Oncol. 13, 186-194.
154. Perera, P. Y., Mayadas, T. N., Takeuchi, O., Akira, S., Zaks-Zilberman, M., Goyert, S. M., Vogel, S. N. (2001) CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression. J. Immunol. 166, 574-581.
155. Tsavaris, N., Kosmas, C., Vadiaka, M., Kanelopoulos, P., Boulamatsis, D. (2002) Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br. J. Cancer 87, 21-27.
156. Machiels, J. P., Reilly, R. T., Emens, L. A., Ercolini, A. M., Lei, R. Y., Weintraub, D., Okoye, F. I., Jaffee, E. M. (2001) Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 61, 3689-3697.
157. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., Kerbel, R. S. (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105, R15-R24.
158. Uddin, S., Sassano, A., Deb, D. K., Verma, A., Majchrzak, B., Rahman, A., Malik, A. B., Fish, E. N., Platanias, L. C. (2002) Protein kinase C-δ (PKC-δ) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J. Biol. Chem. 277, 14408-14416.
159. Ramana, C. V., Chatterjee-Kishore, M., Nguyen, H., Stark, G. R. (2000) Complex roles of Statl in regulating gene expression. Oncogene 19, 2619-2627.
160. Pestka, S. (2003) A dance between interferon-α/β and p53 demonstrates collaborations in tumor suppression and antiviral activities. Cancer Cell 4, 85-87.
161. Slaton, J. W., Perrotte, P., Inoue, K., Dinney, C. P., Fidler, I. J. (1999) Interferon-α-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res. 5, 2726-2734.
162. Madhusudan, S., Protheroe, A., Propper, D., Han, C., Corrie, P., Earl, H., Hancock, B., Vasey, P., Turner, A., Balkwill, F., Hoare, S., Harris, A. L. (2003) A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer. Br. J. Cancer 89, 1418-1422.
163. Curiel, R. E., Garcia, C. S., Farooq, L., Aguero, M. F., Espinoza-Delgado, I. (2001) Bryostatin-1 and IL-2 synergize to induce IFN-γ expression in human peripheral blood T cells: implications for cancer immunotherapy. J. Immunol. 167, 4828-4837.
164. Kovanen, P. E., Junttila, I., Takaluoma, K., Saharinen, P., Valmu, L., Li, W., Silvennoinen, O. (2000) Regulation of Jak2 tyrosine kinase by protein kinase C during macrophage differentiation of IL-3-dependent myeloid progenitor cells. Blood 95, 1626-1632.
165. Ahmed, S. T., Ivashkiv, L. B. (2000) Inhibition of IL-6 and IL-10 signaling and Stat activation by inflammatory and stress pathways. J. Immunol. 165, 5227-5237.
166. Dowlati, A., Lazarus, H. M., Hartman, P., Jacobberger, J. W., Whitacre, C., Gerson, S. L., Ksenich, P., Cooper, B. W., Frisa, P. S., Gottlieb, M., Murgo, A. J., Remick, S. C. (2003) Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies. Clin. Cancer Res. 9, 5929-5935.
167. Wender, P. A., Hinkle, K. W., Koehler, M. F., Lippa, B. (1999) The rational design of potential chemotherapeutic agents: synthesis of bryostatin analogues. Med. Res. Rev. 19, 388-407.
168. Yi, T., Pathak, M. K., Lindner, D. J., Ketterer, M. E., Farver, C., Borden, E. C. (2002) Anticancer activity of sodium stibogluconate in synergy with IFNs. J. Immunol. 169, 5978-5985.
169. Neogy, A. B., Nandy, A., Ghosh, D. B., Chowdhury, A. B. (1988) Modulation of the cell-mediated immune response in kala-azar and post-kala-azar dermal leishmaniasis in relation to chemotherapy. Ann. Trop. Med. Parasitol. 82, 27-34.
170. Da Cruz, A. M., Bittar, R., Mattos, M., Oliveira-Neto, M. P., Nogueira, R., Pinho-Ribeiro, V., Azeredo-Coutinho, R. B., Coutinho, S. G. (2002) T-cell-mediated immune responses in patients with cutaneous or mucosal leishmaniasis: long-term evaluation after therapy. Clin. Diagn. Lab. Immunol. 9, 251-256.
171. Lin, J. X., Leonard, W. J. (2000) The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene 19, 2566-2576.
172. Lotze, M. T. (2000) The future role of interleukin-2 in cancer therapy. Cancer J. Sci. Am. 6 (Suppl. 1), S58-S60.
173. Burton, J., Kay, N. E. (1994) Does IL-2 receptor expression and secretion in chronic B-cell leukemia have a role in down-regulation of the immune system? Leukemia 8, 92-96.
174. McMillan, D. N., Kernohan, N. M., Flett, M. E., Heys, S. D., Deehan, D. J., Sewell, H. F., Walker, F., Eremin, O. (1995) Interleukin 2 receptor expression and interleukin 2 localisation in human solid tumor cells in situ and in vitro: evidence for a direct role in the regulation of tumour cell proliferation. Int. J. Cancer 60, 766-772.
175. Dorfman, D. M., Schultze, J. L., Shahsafaei, A., Michalak, S., Gribben, J. G., Freeman, G. J., Pinkus, G. S., Nadler, L. M. (1997) In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood 90, 4297-4306.
176. Kretzschmar, M., Doody, J., Timokhina, I., Massague, J. (1999) A mechanism of repression of TGFβ/ Smad signaling by oncogenic Ras. Genes Dev. 13, 804-816.
177. Mueller, D. L., Jenkins, M. K., Schwartz, R. H. (1989) Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol. 7, 445-480.
178. Overwijk, W. W., Theoret, M. R., Restifo, N. P. (2000) The future of interleukin-2: enhancing therapeutic anticancer vaccines. Cancer J. Sci. Am. 6 (Suppl. 1), S76-S80.
179. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurts, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., White, D. E. (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Not. Med. 4, 321-327.
180. Ma, X., Trinchieri, G. (2001) Regulation of interleukin-12 production in antigen-presenting cells. Adv. Immunol. 79, 55-92.
181. Wigginton, J. M., Wihrout, B. H. (2002) IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside. Expert Opin. Biol. Ther. 2, 513-524.
182. Kirkwood, J. M., Farkas, D. L., Chakraborty, A., Dyer, K. F., Tweardy, D. J., Abernethy, J. L., Edington, H. D., Donnelly, S. S., Becker, D. (1999) Systemic interferon-α (IFN-α) treatment leads to Stat3 inactivation in melanoma precursor lesions. Mol. Med. 5, 11-20.
183. Belardelli, F., Gresser, I. (1996) The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol. Today, 17, 369-372.
184. Gershenwald, J. E., Buzaid, A. C., Ross, M. I. (1998) Classification and staging of melanoma. Hematol. Oncol. Clin. North Am. 12, 737-765.
185. Kirkwood, J. M., Richards, T., Zarour, H. M., Sosman, J., Ernstoff, M., Whiteside, T. L., Ibrahim, J., Blum, R., Wieand, S., Mascari, R. (2002) Immunomodulatory effects of high-dose and low-dose interferon α2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer 95, 1101-1112.
186. Eriksen, K. W., Kaltoft, K., Mikkelsen, G., Nielsen, M., Zhang, Q., Geisler, C., Nissen, M. H., Ropke, C., Wasik, M. A., Odum, N. (2001) Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia 15, 787-793.
187. Clay, T. M., Hobeika, A. C., Mosca, P. J., Lyerly, H. K., Morse, M. A. (2001) Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin. Cancer Res. 7, 1127-1135.
188. Ito, S., Ansari, P., Sakatsume, M., Dickensheets, H., Vazquez, N., Donnelly, R. P., Larner, A. C., Finbloom, D. S. (1999) Interleukin-10 inhibits expression of both interferon α- and interferon-γ-induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 93, 1456-1463.
189. Spaner, D., Lowsky, R., Fyles, G., Lipton, J. H., Bannerjee, D., Ng, C. M., Wade, J. A., Messner, H. A. (1998) Acute intestinal graft-versus-host disease in a syngeneic bone marrow transplant recipient. Transplantation 66, 1-3.